PharmaEngine

PharmaEngine P/CF

The P/CF (Price-to-Cash-Flow Ratio) of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 5.34. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 20.18 — a change of -73.55% (lower).

P/CF

5.34

YoY

-73.55%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of PharmaEngine is 2025 5.34 . P/CF (Price-to-Cash-Flow Ratio) of PharmaEngine was 2024 20.18 . It decreases by -73.55% lower compared to the previous year.

The PharmaEngine P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
12.37 TWD
Jan 1, 2019
573.27 TWD
Jan 1, 2020
142.31 TWD
Jan 1, 2021
9.91 TWD
Jan 1, 2022
45.63 TWD
Jan 1, 2023
35.87 TWD
Jan 1, 2024
20.18 TWD
Jan 1, 2025
5.34 TWD
The PharmaEngine P/CF history
YEARP/CFYoY
5.34-73.55%
20.18-43.74%
35.87-21.39%
45.63+360.20%
9.91-93.03%
142.31-75.18%
573.27+4,535.07%
12.37-145.53%
-27.16-356.52%
10.59-48.53%
20.57-70.74%
70.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

P/CF (Price-to-Cash-Flow Ratio) of PharmaEngine is 5.34 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of PharmaEngine changed from 20.18 to 5.34, representing a -73.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PharmaEngine

All Key Metrics — PharmaEngine